STAAR SURGICAL CO (STAA) Stock Price & Overview

NASDAQ:STAAUS8523123052

Current stock price

20.21 USD
+0.88 (+4.55%)
At close:
20.31 USD
+0.1 (+0.49%)
After Hours:

The current stock price of STAA is 20.21 USD. Today STAA is up by 4.55%. In the past month the price increased by 8.83%. In the past year, price increased by 26.95%.

STAA Key Statistics

52-Week Range14.69 - 30.81
Current STAA stock price positioned within its 52-week range.
1-Month Range16.83 - 20.32
Current STAA stock price positioned within its 1-month range.
Market Cap
1.001B
P/E
N/A
Fwd P/E
142.99
EPS (TTM)
-1.06
Dividend Yield
N/A

STAA Stock Performance

Today
+4.55%
1 Week
+8.42%
1 Month
+8.83%
3 Months
-14.36%
Longer-term
6 Months -25.53%
1 Year +26.95%
2 Years -56.03%
3 Years -71.32%
5 Years -85.25%
10 Years +162.13%

STAA Stock Chart

STAAR SURGICAL CO / STAA Daily stock chart

STAA Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to STAA. When comparing the yearly performance of all stocks, STAA turns out to be only a medium performer in the overall market: it outperformed 50.77% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

STAA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to STAA. No worries on liquidiy or solvency for STAA as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

STAA Earnings

On March 3, 2026 STAA reported an EPS of -0.37 and a revenue of 57.80M. The company missed EPS expectations (-734.84% surprise) and missed revenue expectations (-24.81% surprise).

Next Earnings DateMay 5, 2026
Last Earnings DateMar 3, 2026
PeriodQ4 / 2025
EPS Reported-$0.37
Revenue Reported57.801M
EPS Surprise -734.84%
Revenue Surprise -24.81%

STAA Forecast & Estimates

16 analysts have analysed STAA and the average price target is 20.12 USD. This implies a price decrease of -0.46% is expected in the next year compared to the current price of 20.21.

For the next year, analysts expect an EPS growth of 113.33% and a revenue growth 15.81% for STAA


Analysts
Analysts52.5
Price Target20.12 (-0.45%)
EPS Next Y113.33%
Revenue Next Year15.81%

STAA Groups

Sector & Classification

STAA Financial Highlights

Over the last trailing twelve months STAA reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS decreased by -421.21% compared to the year before.


Income Statements
Revenue(TTM)239.44M
Net Income(TTM)-80.45M
Industry RankSector Rank
PM (TTM) N/A
ROA -17.81%
ROE -23.37%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%26%
Sales Q2Q%18.08%
EPS 1Y (TTM)-421.21%
Revenue 1Y (TTM)-23.72%

STAA Ownership

Ownership
Inst Owners108.81%
Shares49.51M
Float49.25M
Ins Owners0.31%
Short Float %14.25%
Short Ratio5.02

About STAA

Company Profile

STAA logo image STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.

Company Info

IPO: 1992-02-24

STAAR SURGICAL CO

1911 Walker Ave

Monrovia California CALIFORNIA 92630 US

CEO: Caren Mason

Employees: 957

STAA Company Website

STAA Investor Relations

Phone: 16263037902

STAAR SURGICAL CO / STAA FAQ

What does STAA do?

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.


What is the stock price of STAAR SURGICAL CO today?

The current stock price of STAA is 20.21 USD. The price increased by 4.55% in the last trading session.


Does STAAR SURGICAL CO pay dividends?

STAA does not pay a dividend.


How is the ChartMill rating for STAAR SURGICAL CO?

STAA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Can you provide the growth outlook for STAAR SURGICAL CO?

The Revenue of STAAR SURGICAL CO (STAA) is expected to grow by 15.81% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the employee count for STAA stock?

STAAR SURGICAL CO (STAA) currently has 957 employees.


What is the outstanding short interest for STAAR SURGICAL CO?

The outstanding short interest for STAAR SURGICAL CO (STAA) is 14.25% of its float.